<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232033</url>
  </required_header>
  <id_info>
    <org_study_id>H-19068397</org_study_id>
    <nct_id>NCT04232033</nct_id>
  </id_info>
  <brief_title>The Physiological Effects of FGF21 on Alcohol Preference and Glucose Metabolism</brief_title>
  <acronym>AlcoDep</acronym>
  <official_title>The Physiological Effects of FGF21 on Alcohol Preference and Glucose Metabolism in Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Novo Nordisk Foundation Center for Basic Metabolic Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate taste preferences for alcohol during an intravenous
      infusion of the naturally occurring hormone fibroblast growth factor-21 (FGF21) and placebo
      (i.e. saline), respectively, in 20 healthy subjects. Secondary endpoints are to evaluate the
      effects of exogenous FGF21 (compared to placebo) on resting energy expenditure, preference
      for salt, sour and bitter taste qualities, sensations of hunger, thirst, appetite, satiety,
      headache and nausea, and makers of glucose metabolism (e.g. plasma/serum concentrations of
      glucose, C-peptide, insulin and glucagon).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol preference (How much do you want to drink alcohol?)</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluated by Visual analogue scale from &quot;not at all&quot; to &quot;more than ever&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose concentration</measure>
    <time_frame>1 year</time_frame>
    <description>Plasma glucose concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin concentration</measure>
    <time_frame>1 year</time_frame>
    <description>Serum insulin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma fibroblast growth factor-21 concentration</measure>
    <time_frame>1 year</time_frame>
    <description>Plasma fibroblast growth factor-21 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-peptide concentration</measure>
    <time_frame>1 year</time_frame>
    <description>Serum C-peptide concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucagon concentration</measure>
    <time_frame>1 year</time_frame>
    <description>Serum C-peptide concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma lipid profile</measure>
    <time_frame>1 year</time_frame>
    <description>Plasma concentrations of triglycerides, total cholesterol, free fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin-like growth factor 1 concentration</measure>
    <time_frame>1 year</time_frame>
    <description>Plasma insulin-like growth factor 1 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma bone marker concentration</measure>
    <time_frame>1 year</time_frame>
    <description>Plasma concentrations of the bone markers carboxy-terminal collagen crosslink and procollagen type 1 N-terminal propeptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting energy expenditure</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluated by indirect calorimetry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Fibroblast Growth Factor 21</condition>
  <condition>Tast Perference</condition>
  <arm_group>
    <arm_group_label>Fibroblast growth factor 21 infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fibroblast growth factor 21 infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo infusion (saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fibroblast growth factor 21 infusion</intervention_name>
    <description>Infusion of Fibroblast growth factor 21</description>
    <arm_group_label>Fibroblast growth factor 21 infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo infusion (saline)</intervention_name>
    <description>Infusion of Saline</description>
    <arm_group_label>Placebo infusion (saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Caucasian male

          -  Body mass index between 19 and 27 kg/m2

          -  Normal haemoglobin and normal glycated haemoglobin A1c (HbA1c) (&lt; 42 mmol/mol)

          -  Weekly alcohol intake of less than 14 units of alcohol (1 unit = 12 g ethanol)

        Exclusion Criteria:

          -  Liver diseases evaluated by plasma alanine aminotransferase (ALAT) &gt; 3 Ã— normal level
             or an International Normalized Ratio (INR) below normal values

          -  Diabetes mellitus

          -  Nephropathy

          -  First-degree relatives with diabetes and/or liver diseases and/or alcohol use disorder

          -  Other diseases the investigator finds disruptive for participation in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amalie R Lanng, Dr.</last_name>
    <phone>+45 21649983</phone>
    <email>amalie.rasmussen.lanng@regionh.dk</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

